Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T1-2N0M0 breast cancer

Polish Journal of Pathology

Volumn 64, Issue 1, 2013, Pages 1-8

  Gudlaugsson, Einar ^a   Klos, Jan ^a   Skaland, Ivar ^a   Janssen, Emiel A M ^a   Smaaland, Rune ^a   Feng, Weiwei ^b   Shao, Zhimin ^c   Malpica, Anais ^d   Baak, Jan P A ^a,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Automation; Breast cancer; Ki67; Mitosis; Phosphohistone H3; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE; KERATIN; KI 67 ANTIGEN; STEROID RECEPTOR; TUMOR MARKER;

AGED; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MITOSIS INDEX; MORTALITY; NORWAY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HISTONES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KERATINS; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; NORWAY; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 84876974897     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.34596     Document Type: Article

References (18)

1. Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet 2005; 365: 1727-1741.
2. Adjuvant! Online, at http://www.adjuvantonline.com.
3. Boyages J, Chua B, Taylor R, et al. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 2002; 89: 789-796.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
5. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23: 5993-6001.
6. Skaland I, Janssen EA, Gudlaugsson E, et al. Validating the prognostic value of proliferation measured by PPH3 (phosphohistone H3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat 2009; 115: 39-45.
7. Baak JP, Gudlaugsson E, Skaland I, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 2009; 115: 241-254.
8. Lende TH, Janssen EA, Gudlaugsson E, et al. In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to Adjuvant! J Clin Oncol 2011; 29: 852-858.
9. Gudlaugsson E, Skaland I, Janssen EA, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 2012; 61: 1134-1144.
10. McShane LM, Atman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker studies. J Clin Oncol 2005; 23: 9067-9072.
11. Pathology and Genetics: Tumors of the Breast and Female Genital Tract Organs; WHO Classification of Tumours Series. Tavas-soli FA, Devilee P (eds.). IARC Press Lyon 2003; 9-112.
12. Ellis IO, Schnitt SJ, Sastre-Garu X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P (eds). Pathology and Genetics of the Female Genital Tract Organs. IARC Press, Lyon 2003; 18-19.
13. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility of mitoses counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992; 23: 603-607.
14. Jannink I, Risberg B, van Diest PJ, et al. Heterogeneity of mitotic activity in breast cancer. Histopatology 1996; 29: 421-428.
15. Bergers E, Jannink I, van Diest PJ, et al. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol 1997; 28: 95-100.
16. Gudlaugsson E, Skaland I, Undersrud E, et al. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Mod Pathol 2011; 24: 502-511.
17. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 la-belling for histoprognostic grading of breast adenocarcinomas and computer assisted determination of mitotic index. J Clin Pathol 2006; 59: 706-710.
18. Skaland I, Janssen EA, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007; 12: 1307-1315.